Your browser doesn't support javascript.
loading
Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma).
Drakaki, Alexandra; Powles, Thomas; Bamias, Aristotelis; Martin-Liberal, Juan; Shin, Sang Joon; Friedlander, Terence; Tosi, Diego; Park, Chandler; Gomez-Roca, Carlos; Joly Lobbedez, Florence; Castellano, Daniel; Morales-Barrera, Rafael; Moreno-Candilejo, Irene; Fléchon, Aude; Yuen, Kobe; Rishipathak, Deepali; DuPree, Kelly; Young, Fiona; Michielin, Francesca; Shemesh, Colby S; Steinberg, Elizabeth E; Williams, Patrick; Lee, Jae Lyun.
Afiliación
  • Drakaki A; Division of Hematology and Oncology, UCLA David Geffen School of Medicine, Los Angeles, California.
  • Powles T; Barts Cancer Centre, Barts Health NHS Trust, Queen Mary University of London, London, United Kingdom.
  • Bamias A; National and Kapodistrian University of Athens, Athens, Greece.
  • Martin-Liberal J; Medical Oncology Department, Catalan Institute of Oncology (ICO) Hospitalet, Barcelona, Spain.
  • Shin SJ; Yonsei Cancer Center, Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.
  • Friedlander T; University of California San Francisco, Helen Diller Family Cancer Center, San Francisco, California.
  • Tosi D; Institut régional du Cancer de Montpellier (ICM), Montpellier, France.
  • Park C; Norton Cancer Institute, Louisville, Kentucky.
  • Gomez-Roca C; Department of Medical Oncology, Institut Claudius Regaud/IUCT Oncopole, Toulouse, France.
  • Joly Lobbedez F; Centre Francois-Baclesse, Medical Oncology, Caen, France.
  • Castellano D; Hospital 12 de Octubre, Madrid, Spain.
  • Morales-Barrera R; Vall d'Hebron Institute of Oncology, Vall d' Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Moreno-Candilejo I; START Madrid Phase I Unit, Hospital Sanchinarro, Madrid, Spain.
  • Fléchon A; Centre Léon Bérard, Lyon, France.
  • Yuen K; Genentech, Inc., South San Francisco, California.
  • Rishipathak D; Genentech, Inc., South San Francisco, California.
  • DuPree K; Genentech, Inc., South San Francisco, California.
  • Young F; Roche Products Ltd, Welwyn Garden City, United Kingdom.
  • Michielin F; Roche Innovation Center Basel, Basel, Switzerland.
  • Shemesh CS; Genentech, Inc., South San Francisco, California.
  • Steinberg EE; Genentech, Inc., South San Francisco, California.
  • Williams P; Genentech, Inc., South San Francisco, California.
  • Lee JL; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Clin Cancer Res ; 29(21): 4373-4384, 2023 11 01.
Article en En | MEDLINE | ID: mdl-37651261
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Vejiga Urinaria / Carcinoma de Células Transicionales / Neoplasias Urológicas Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Vejiga Urinaria / Carcinoma de Células Transicionales / Neoplasias Urológicas Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article